AVT06
-
Alvotech and Teva Set for U.S. Court Date on AVT06, Eylea® Biosimilar Challenge
Alvotech has settled with Regeneron, clearing a path for its biosimilar AVT06 (aflibercept) to potentially enter the U.S. market in late 2026, pending FDA approval. This agreement, alongside a partnership with Teva Pharmaceuticals, follows AVT06’s recent marketing approvals in the UK, Japan, and the EEA. Clinical studies have confirmed AVT06’s high degree of similarity to Eylea®, positioning it as a more affordable alternative for retinal diseases.
